Ten weeks. Four hundred thousand patients. Oral Wegovy has become the fastest-adopted obesity medication in American history, and the numbers are still accelerating. Esanum reported Monday that approximately 400,000 Americans were estimated to be taking the pill form of semaglutide within the first ten weeks of its broad availability, which began after FDA approval on January 5, 2026 [1].

As we detailed in our previous coverage, the oral formulation removes what patients and physicians consistently identified as the primary barrier to GLP-1 adoption: the injection. Weekly self-injection, even with thin-gauge autoinjectors, kept millions of eligible patients from starting treatment. A daily pill is something Americans understand, accept, and will take consistently [2].

The clinical data supports the enthusiasm. In the Phase 3 OASIS 4 trial, once-daily oral semaglutide produced approximately 21 percent weight loss at 72 weeks in adults with obesity, numbers comparable to the injectable version [3]. The convenience trade-off -- daily versus weekly dosing -- appears to be one most patients are happy to make.

Novo Nordisk, which manufactures both injectable and oral Wegovy, has acknowledged that demand has exceeded supply projections. Pharmacy shortages have been reported in New York, Los Angeles, and Chicago, echoing the supply constraints that plagued the injectable version in 2023 and 2024 [4].

The competitive landscape is shifting rapidly. Eli Lilly's oral tirzepatide is in late-stage trials, and Pfizer's oral GLP-1 candidate, danuglipron, is expected to file for approval later this year. But for now, oral Wegovy has first-mover advantage in a market that Goldman Sachs projects will reach $100 billion annually by 2030.

The 400,000 figure understates total oral GLP-1 use because it excludes compounded versions, which telehealth platforms like Hims and Ro began offering within weeks of the FDA approval. The compounding market, while legally contested by Novo Nordisk, has made oral semaglutide accessible at a fraction of the brand-name price.

For the obesity treatment field, the pill represents an inflection point. Injectable GLP-1 drugs proved the drugs worked. The pill proves that Americans will take them. The combination of clinical efficacy, oral convenience, and expanding insurance coverage means that the patient population for anti-obesity medication has effectively doubled overnight.

Health economists project that if even half of the clinically eligible American population eventually adopts oral GLP-1 therapy, the downstream effects on healthcare costs, food industry revenue, and life insurance actuarial tables will be measurable within three years.

-- NORA WHITFIELD, New York